Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 16;15(10):e0322023.
doi: 10.1128/mbio.03220-23. Epub 2024 Sep 16.

Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants

Collaborators, Affiliations
Review

Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants

Hisano Yajima et al. mBio. .

Abstract

Due to the incessant emergence of various SARS-CoV-2 variants with enhanced fitness in the human population, controlling the COVID-19 pandemic has been challenging. Understanding how the virus enhances its fitness during a pandemic could offer valuable insights for more effective control of viral epidemics. In this manuscript, we review the evolution of SARS-CoV-2 from early 2022 to the end of 2023-from Omicron BA.2 to XBB descendants. Focusing on viral evolution during this period, we provide concrete examples that SARS-CoV-2 has increased its fitness by enhancing several functions of the spike (S) protein, including its binding affinity to the ACE2 receptor and its ability to evade humoral immunity. Furthermore, we explore how specific mutations modify these functions of the S protein through structural alterations. This review provides evolutionary, molecular, and structural insights into how SARS-CoV-2 has increased its fitness and repeatedly caused epidemic surges during the pandemic.

Keywords: Omicron; SARS-CoV-2; evolution; molecular phylogenetic; spike; structural biology.

PubMed Disclaimer

Conflict of interest statement

J.I. has consulting fees and honoraria for lectures from Takeda Pharmaceutical Co. Ltd. K.S. has consulting fees from Moderna Japan Co., Ltd., and Takeda Pharmaceutical Co. Ltd. and honoraria for lectures from Gilead Sciences, Inc., Moderna Japan Co., Ltd., and Shionogi & Co., Ltd. The other authors declare no competing interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the paper have been disclosed.

Figures

Fig 1
Fig 1
Epidemiology and evolution of BA.2-related lineages. (A) Repeated transitions of epidemic SARS-CoV-2 lineages from 1 November 2021 to 29 February 2024. The source data were obtained from GISAID (https://gisaid.org/; EPI SET ID: EPI_SET_240423yq). (B) Schematic lineage tree of major epidemic lineages provided by Nextclade. This figure was sourced from Nextclade (https://clades.nextstrain.org/) and used under the CC-BY 4.0 license. (C) Comparison of mutations in the S protein among major lineages. When different types of substitutions occur at the same amino acid position, these substitutions are displayed together, indicating the types of substitutions. The source data were obtained from GISAID (EPI SET ID: EPI_SET_240423yq).
Fig 2
Fig 2
Structural and virological summaries of the evolution of BA.2-related lineages. (A) A schematic of descendants after BA.2 was sorted over time (refer to Fig. 1A). The ACE2-binding affinity and neutralizing antibody evasion ability compared to those of the ancestral lineage on the left are shown under each variant name. In each variant, the cryo-EM structure or schematic of the S protein trimer alone is shown in the bottom left, and the zoom-up view of the mutation of interest for each variant is shown in the bottom right. PDB IDs: BA.5, 7XWA; BA.2.75, 8ASY; BQ.1.1, 8IF2; XBB.1, 8IOV; XBB.1.5, 8JYP; EG.5.1, 8XLN. EMDB IDs: BA.5, 33325; BA.2.75, 34221; XBB.1, 35622; XBB.1.5, 36724; EG.5.1, 37651. (B) A schematic diagram of the sequence gap bordered before/after BA.1 and the structural gap bordered before/after BA.2. In sequences, the difference between pre-Omicron and Omicron is obvious, but in the RBD up/down states of the S proteins, they are separated at the boundary of BA.1 and BA.2. In the structures of S-protein trimer, the RBDs are highlighted in red (the other areas are gray).

References

    1. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A. 2023. The evolution of SARS-CoV-2. Nat Rev Microbiol 21:361–379. doi:10.1038/s41579-023-00878-2 - DOI - PubMed
    1. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Peacock SJ, Barclay WS, de Silva TI, Towers GJ, Robertson DL, COVID-19 Genomics UK Consortium . 2023. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 21:162–177. doi:10.1038/s41579-022-00841-7 - DOI - PMC - PubMed
    1. Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I, Uriu K, Kosugi Y, et al. . 2021. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 29:1124–1136. doi:10.1016/j.chom.2021.06.006 - DOI - PMC - PubMed
    1. Ferreira I, Kemp SA, Datir R, Saito A, Meng B, Rakshit P, Takaori-Kondo A, Kosugi Y, Uriu K, Kimura I, Shirakawa K, Abdullahi A, Agarwal A, Ozono S, Tokunaga K, Sato K, Gupta RK, CITIID-NIHR BioResource COVID-19 Collaboration, Indian SARS-CoV-2 Genomics Consortium, Genotype to Phenotype Japan (G2P-Japan) Consortium . 2021. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J Infect Dis 224:989–994. doi:10.1093/infdis/jiab368 - DOI - PMC - PubMed
    1. Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-A, Kaneda A, Nakagawa S, Sato K, Genotype to Phenotype Japan (G2P-Japan) Consortium . 2021. Neutralization of the SARS-CoV-2 mu variant by convalescent and vaccine serum. N Engl J Med 385:2397–2399. doi:10.1056/NEJMc2114706 - DOI - PMC - PubMed

MeSH terms

Substances

Supplementary concepts

Grants and funding

LinkOut - more resources